Yes

Who we are

  • April 5, 2022
    Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
  • April 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • April 5, 2022
    Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer
  • April 5, 2022
    Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
  • April 5, 2022
    Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
  • April 5, 2022
    A study looking at using a vaccine and chemotherapy to treat advanced cancer
  • April 5, 2022
    METIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin
  • April 5, 2022
    Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
  • April 5, 2022
    Nivolumab+Ipilimumab+RT in MSS mCRC
  • April 5, 2022
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)